soul trial oral semaglutide cardiovascular outcomes 2025 Frontiers SOUL trial shows oral semaglutide

patients with family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 need to avoid GLP-1 products entirely for safety concerns

Why physicians favor drugs over diet Some large proportion of physicians will always prefer drug therapy to dietary alternatives

It was noted that setmelanotide would be the first available therapy to target the underlying mechanism of BBS-associated hyperphagia, and that setmelanotide would not be expected to have an impact on manifestations in other body systems (e.g., ocular manifestations)

They correspond to the previously reported AP GLU10 Calcr/Ramp3 population combined with the Glp1r/Casr/Tnfrsf11b -expressing subpopulation (GLU4a in ref